{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:27:39Z","timestamp":1787225259577,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Metab Health Dis"],"DOI":"10.1038\/s44324-026-00126-0","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:01:05Z","timestamp":1787223665000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reappraising obesity management in the GLP-1 receptor agonist era"],"prefix":"10.1038","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1828-8298","authenticated-orcid":false,"given":"T.","family":"Christmas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8349-4688","authenticated-orcid":false,"given":"A. R.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5873-3432","authenticated-orcid":false,"given":"T. M-M.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"126_CR1","unstructured":"World Obesity Federation. World Obesity Atlas 2025 [Internet]. London: World Obesity Federation. https:\/\/data.worldobesity.org\/publications\/world-obesity-atlas-2025-v6.pdf (2025)."},{"key":"126_CR2","doi-asserted-by":"crossref","unstructured":"Drucker, D. J. & Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368, 1696\u20131705 (2006).","DOI":"10.1016\/S0140-6736(06)69705-5"},{"key":"126_CR3","doi-asserted-by":"crossref","unstructured":"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989\u20131002 (2021).","DOI":"10.1056\/NEJMoa2032183"},{"key":"126_CR4","doi-asserted-by":"crossref","unstructured":"Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 389, 2221\u20132232 (2023).","DOI":"10.1056\/NEJMoa2307563"},{"key":"126_CR5","doi-asserted-by":"crossref","unstructured":"Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205\u2013216 (2022).","DOI":"10.1056\/NEJMoa2206038"},{"key":"126_CR6","doi-asserted-by":"crossref","unstructured":"Aronne, L. J. et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N. Engl. J. Med. 393, 26\u201336 (2025).","DOI":"10.1056\/NEJMoa2416394"},{"key":"126_CR7","unstructured":"Eli Lilly and Company. Lilly\u2019s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial [press release on the Internet]. PR Newswire. https:\/\/www.prnewswire.com\/news-releases\/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-302638804.html (2025)."},{"key":"126_CR8","doi-asserted-by":"crossref","unstructured":"Wharton, S. et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N. Engl. J. Med. 393, 1077\u20131087 (2025).","DOI":"10.1056\/NEJMoa2500969"},{"key":"126_CR9","doi-asserted-by":"crossref","unstructured":"Wharton, S. et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N. Engl. J. Med. 393, 1796\u20131806 (2025).","DOI":"10.1056\/NEJMoa2511774"},{"key":"126_CR10","doi-asserted-by":"crossref","unstructured":"Wilding, J. P. H. et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diab. Obes. Metab. 24, 1553\u20131564 (2022).","DOI":"10.1111\/dom.14725"},{"key":"126_CR11","doi-asserted-by":"crossref","unstructured":"Sj\u00f6str\u00f6m, L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J. Intern. Med. 273, 219\u2013234 (2013).","DOI":"10.1111\/joim.12012"},{"key":"126_CR12","doi-asserted-by":"crossref","unstructured":"Abbott et al. Roux-en-Y gastric bypass, adjustable gastric banding, or sleeve gastrectomy for severe obesity (By-Band-Sleeve): a multicentre, open label, three-group, randomised controlled trial. Lancet Diab. Endocrinol. 13, 410\u2013426 (2025).","DOI":"10.1016\/S2213-8587(25)00025-7"},{"key":"126_CR13","doi-asserted-by":"crossref","unstructured":"Hazlehurst, J. et al. Society for endocrinology guidelines for the diagnosis and management of post-bariatric hypoglycaemia. Endocr. Connect 13, e230285 (2024).","DOI":"10.1530\/EC-23-0285"},{"key":"126_CR14","doi-asserted-by":"crossref","unstructured":"Gasoyan, H. et al. Macrovascular and microvascular outcomes of metabolic surgery versus GLP-1 receptor agonists in patients with diabetes and obesity. Nat. Med. 31, 3341\u20133349 (2025).","DOI":"10.1038\/s41591-025-03893-3"},{"key":"126_CR15","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/oby.70100","volume":"34","author":"L Sabatella","year":"2026","unstructured":"Sabatella, L. et al. Comparative efficacy of metabolic\/bariatric surgery versus GLP-1 receptor agonists: a network meta-analysis of randomized controlled trials. Obesity 34, 770\u2013781 (2026).","journal-title":"Obesity"},{"key":"126_CR16","doi-asserted-by":"crossref","unstructured":"Barrett, T. S., Hafermann, J. O., Richards, S., LeJeune, K. & Eid, G. M. Obesity treatment with bariatric surgery vs GLP-1 receptor agonists. JAMA Surg. 160, 1232\u20131239 (2025).","DOI":"10.1001\/jamasurg.2025.3590"}],"container-title":["npj Metabolic Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44324-026-00126-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44324-026-00126-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44324-026-00126-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:01:09Z","timestamp":1787223669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44324-026-00126-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["126"],"URL":"https:\/\/doi.org\/10.1038\/s44324-026-00126-0","relation":{},"ISSN":["2948-2828"],"issn-type":[{"value":"2948-2828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.M-M. Tan is a former shareholder in, consultant for and founder of Zihipp Ltd. Currently serving in advisory boards for Nxera and Amylyx. T. Christmas and A.R. Ahmed have no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"34"}}